BioPharma Dive October 28, 2024
David Epstein has joined Ottimo Pharma, which is developing a dual-targeting antibody drug that board member James Sabry claims could “change the face of cancer immunotherapy.”
The former head of cancer drugmaker Seagen has joined a new startup involved in what’s recently become a competitive corner of oncology research.
The startup, Ottimo Pharma, emerged from stealth Monday with the backing of U.K. venture firm Medicxi and David Epstein as its chairman and CEO. It is developing a type of cancer drug that blocks two molecular pathways — PD-1 and VEGF — implicated in tumors’ ability to grow and evade detection from the immune system. The company intends to ask regulators next year to begin its first clinical trial.
The startup...
Today's Sponsors
Today's Sponsor